• 1. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 4. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 5. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzene and substituted derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives

Introduction to 4-(1-(Hydroxymethyl)cyclopropyl)phenylboronic Acid (CAS No. 1217501-10-4)

4-(1-(Hydroxymethyl)cyclopropyl)phenylboronic acid is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and materials science due to its unique structural properties and potential applications. This compound, identified by its CAS number 1217501-10-4, features a boronic acid functional group attached to a phenyl ring, which is further substituted with a cyclopropyl group containing a hydroxymethyl moiety. The combination of these structural elements imparts distinct chemical reactivity and biological relevance, making it a subject of interest for researchers exploring novel synthetic pathways and therapeutic agents.

The boronic acid component of this molecule is particularly noteworthy, as boronic acids are widely recognized for their role in various biological processes and their utility in pharmaceutical applications. Boronic acids exhibit the ability to form stable complexes with diols, a property that has been leveraged in the development of drugs targeting diseases such as cancer and diabetes. For instance, the boron-containing compound pazopanib, an antiangiogenic agent used in cancer therapy, incorporates a boronic acid moiety to enhance its binding affinity and efficacy.

Recent advancements in medicinal chemistry have highlighted the importance of cyclopropyl-substituted compounds in drug design. The cyclopropyl group, being a small, rigid ring structure, can influence the conformational flexibility and electronic properties of molecules. In the case of 4-(1-(Hydroxymethyl)cyclopropyl)phenylboronic acid, the presence of this group adjacent to the phenyl ring and boronic acid functionality may contribute to unique interactions with biological targets. This has prompted investigations into its potential as a scaffold for developing new pharmacological agents.

The hydroxymethyl substituent on the cyclopropyl ring adds another layer of complexity to the molecule's chemical behavior. Hydroxymethyl groups are known to participate in hydrogen bonding and can influence solubility and metabolic stability. In drug development, such functional groups are often strategically incorporated to modulate pharmacokinetic properties. The interplay between the hydroxymethyl, cyclopropyl, and phenylboronic acid components may enable this compound to exhibit novel biological activities that are not observed with simpler analogs.

Current research in the field of boron chemistry has been increasingly focused on exploring new derivatives of boronic acids for therapeutic applications. The ability of boronic acids to form reversible covalent bonds with biomolecules has opened up possibilities for targeted drug delivery systems and protease inhibition strategies. For example, research has demonstrated that boronic acid-containing compounds can selectively interact with enzymes such as cathepsin K, which is overexpressed in certain pathological conditions like osteoporosis. The structural features of 4-(1-(Hydroxymethyl)cyclopropyl)phenylboronic acid may make it a valuable candidate for similar applications.

The synthesis of this compound involves sophisticated organic transformations that highlight the ingenuity of modern synthetic chemistry. The introduction of the cyclopropyl group necessitates careful consideration of reaction conditions to ensure regioselectivity and yield optimization. Advanced techniques such as transition-metal-catalyzed cross-coupling reactions have been employed to construct the desired carbon-carbon bonds efficiently. These synthetic strategies not only contribute to the accessibility of 4-(1-(Hydroxymethyl)cyclopropyl)phenylboronic acid but also advance the broader field of organic synthesis by demonstrating innovative approaches to constructing complex molecular architectures.

In addition to its pharmaceutical potential, this compound may find applications in materials science, particularly in areas requiring functional organic molecules with specific chemical properties. For instance, boronic acids are known to participate in coordination chemistry and can be used to develop metal-organic frameworks (MOFs) or supramolecular assemblies. The unique combination of structural elements in 4-(1-(Hydroxymethyl)cyclopropyl)phenylboronic acid could make it suitable for designing novel materials with tailored properties.

The exploration of this compound's biological activity has been facilitated by computational modeling techniques, which allow researchers to predict how it might interact with biological targets based on its three-dimensional structure. Molecular docking studies have been particularly useful in identifying potential binding sites on proteins or enzymes relevant to therapeutic intervention. These computational approaches complement experimental efforts by providing insights into the likely mechanisms of action and guiding further optimization efforts.

Future research directions may include evaluating the pharmacological profile of derivatives derived from 4-(1-(Hydroxymethyl)cyclopropyl)phenylboronic acid. By modifying specific functional groups or introducing additional substituents, researchers can fine-tune the properties of these compounds to enhance their efficacy or reduce potential side effects. Such modifications would be guided by both experimental data and theoretical predictions, leveraging interdisciplinary collaboration between chemists, biologists, and computer scientists.

The broader significance of this compound lies in its representation of the intersection between organic chemistry, medicinal chemistry, and materials science. As our understanding of molecular interactions continues to evolve, compounds like 4-(1-(Hydroxymethyl)cyclopropyl)phenylboronic acid will serve as valuable tools for exploring new frontiers in science and technology. Their development not only promises advancements in human health but also contributes to our fundamental understanding of how molecules function at the most basic level.

• 302333-80-8((4-Cyclopropylphenyl)boronic acid)
• 850568-48-8(4-(3-Hydroxypropyl)phenylboronic acid)
• 851199-87-6(BORONIC ACID, [4-(1,1-DIMETHYLPROPYL)PHENYL]-)
• 865360-61-8(BORONIC ACID, [4-(4,4-DIMETHYLCYCLOHEXYL)PHENYL]-)
• 186498-04-4(Boronic acid, [4-(2,2-dimethylpropyl)phenyl]-)
• 1264296-84-5(4-(1-methylcyclopropyl)phenylboronic acid)
• 736989-98-3(3-(3-Hydroxypropyl)phenylboronic Acid)
• 850568-56-8((4-sec-Butylphenyl)boronic Acid)
• 1049730-10-0((3-Cyclopropylphenyl)boronic Acid)
• 1159489-46-9(1-(4-Boronophenyl)cyclopropanecarboxylic acid)